More had been a GP at the firm since he joined the team in 2008 and was a member of its biopharma team.
His new role will see him focus on life sciences investment which tallies with the Gates Foundation’s drive for global health and development programmes.
More has almost two decades of experience in the life sciences investment sector, previously as a partner with Domain Associates.
He joined that firm in 1996 and became a partner four years later.
More has been involved in investments and sat on the boards of businesses including ESP Pharma, Proxima Therapeutics and Onux Medical.
He also serves as an advisory board member for Greenspring Associates, Okapi Ventures, the medical industry group of US venture capital lobby body NVCA and The Sulpizio Family Cardiovascular Center.
A total of 20 investors had committed to the $300m-targeting Frazier Healthcare VII according to a US securities filing at the time, which said the total collected including three per cent from the general partner.
The firm, which exclusively targets healthcare, medical device and biotechnology investments, last gathered capital in 2007 through its $600m sixth fund.
Copyright © 2013 AltAssets